Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 26;10(9):1253-1267.
doi: 10.1002/mdc3.13810. eCollection 2023 Sep.

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Prashanth Lingappa Kukkle  1   2 , Divyani Garg  3 , Marcello Merello  4
Affiliations

Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Prashanth Lingappa Kukkle et al. Mov Disord Clin Pract. .

Abstract

Background: Continuous subcutaneous apomorphine infusion (CSAI) is one of the advanced therapies for Parkinson's disease (PD).

Methods: A systematic review of all published articles in English on CSAI for PD till January 30, 2022 was conducted.

Results: A total of 82 articles met the search criteria. Publications included retrospective or prospective open-label observational studies, with a limited number of randomized control trials (RCT). Publications were highly heterogeneous and focused on different aspects of CSAI and included clinical audits, effects on cognition/behavior, axial symptoms, nocturnal issues, adverse events/reasons for discontinuation and comparison with other continuous dopaminergic therapies. CSAI was used in patients who presented severe motor fluctuations not resolved by oral therapy, poor candidates for deep brain stimulation (DBS) due to cognitive/behavioral issues or in those with DBS weaning effect. Recent studies have also shown that CSAI was useful for nocturnal usage in advanced PD, in addition to daytime utilization. Adverse effects were common and include skin lesions, sedation and nausea. Pump management difficulties and patient decisions were common reasons for therapy dropout, predominantly during the initial stages of the CSAI.

Conclusion: There is consistent agreement on the benefits of CSAI in reducing OFF periods and improving ON periods without troublesome dyskinesia and specific motor and non-motor symptoms. Although there is a paucity of RCTs, current data from almost 30 years of use suggests CSAI to be beneficial in advanced cases of PD.

Keywords: CSAI systematic review; Parkinson's disease; apomorphine; continuous infusion delivery; infusion therapies; motor symptoms; non‐motor symptoms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The PRISMA flow chart. Panel‐1: search criteria. MeSH keyword “Apomorphine” (“Apomorphine”[Mesh] OR Apomorphine[tw] OR “Apomorphine infusion”[tw] OR “Apomorphine Subcutaneous infusion”[tw]) and “Parkinson Disease”[Mesh] OR “Parkinsonian Disorders”[Mesh], were used for the search. All studies up to January 30, 2022, in English and involving human subjects were shortlisted.
See this image and copyright information in PMC

References

    1. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;56:251–253. - PubMed
    1. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979;1(8123):954–956. - PubMed
    1. Obeso JA, Grandas F, Vaamonde J, Rosario Luguin M, Martínez‐Lage JM. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet 1987;1(8546):1376–1377. - PubMed
    1. Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000;15(5):789–794. - PubMed
    1. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. - PMC - PubMed

Publication types

MeSH terms